Tumor-shed antigen CA125 blocks complement-mediated killing via suppression of C1q-antibody binding.

Tumor-shed antigen CA125 blocks complement-mediated killing via suppression of C1q-antibody binding.

C1q-engagement with IgG and IgM sort antibodies is the initiating step of classical complement-mediated immunity. The tumor shed antigen CA125 has been reported to have immunosuppressive results on host tumor responses in addition to commercially authorized and experimental monoclonal antibody (mAb)-based therapeutic brokers. To raised perceive this impact, molecular and mobile research had been carried […]